COSCIENS Biopharma Inc. Key Management Personnel Compensation
COSCIENS Biopharma Inc. (CSCIF) reported Key Management Personnel Compensation of $2.46 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:KeyManagementPersonnelCompensation · last filed 2026-03-25
- COSCIENS Biopharma Inc. key management personnel compensation for the quarter ending 2022-03-31 was $406.00K, a 40.48% increase year-over-year.
- COSCIENS Biopharma Inc. key management personnel compensation for the quarter ending 2021-12-31 was $765.00K, a 4.14% decline year-over-year.
- COSCIENS Biopharma Inc. key management personnel compensation for the quarter ending 2021-09-30 was $412.00K, a 6.79% decline year-over-year.
- COSCIENS Biopharma Inc. key management personnel compensation for the quarter ending 2021-06-30 was $708.00K.
| Period end | Key Management Personnel Compensation 3 month | Key Management Personnel Compensation 6 month | Key Management Personnel Compensation 9 month | Key Management Personnel Compensation 12 month | Key Management Personnel Compensation 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $2.46M 20-F · filed 2026-03-25 | ||||
| 2024-12-31 | $2.02M 20-F · filed 2026-03-25 | ||||
| 2023-12-31 | $1.47M 20-F · filed 2026-03-25 | $2.35M 20-F · filed 2024-03-27 | |||
| 2022-12-31 | $1.01M 20-F · filed 2025-04-09 | $2.39M 20-F · filed 2023-03-23 | |||
| 2022-03-31 | $406.00K 6-K · filed 2022-05-11 | $1.17M derived: sum of 2 quarters · filed 2024-07-17 | $1.58M derived: sum of 3 quarters · filed 2024-07-17 | $2.29M derived: sum of 4 quarters · filed 2024-07-17 | |
| 2021-12-31 | $765.00K derived: 20-F/A 12 month − 6-K 9 month · filed 2024-07-17 | $1.18M derived: sum of 2 quarters · filed 2024-07-17 | $1.89M derived: sum of 3 quarters · filed 2024-07-17 | $2.17M 20-F/A · filed 2024-07-17 | |
| 2021-09-30 | $412.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-11-04 | $1.12M derived: sum of 2 quarters · filed 2021-11-04 | $1.41M 6-K · filed 2021-11-04 | $2.21M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-06-30 | $708.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-08-05 | $997.00K 6-K · filed 2021-08-05 | $1.79M derived: sum of 3 quarters · filed 2024-02-15 | $2.24M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-03-31 | $289.00K 6-K · filed 2022-05-11 | $1.09M derived: sum of 2 quarters · filed 2024-02-15 | $1.53M derived: sum of 3 quarters · filed 2024-02-15 | ||
| 2020-12-31 | $798.00K derived: 20-F/A 12 month − 6-K 9 month · filed 2024-02-15 | $1.24M derived: sum of 2 quarters · filed 2024-02-15 | $1.95M 20-F/A · filed 2024-02-15 | ||
| 2020-09-30 | $442.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-11-04 | $1.16M 6-K · filed 2021-11-04 | |||
| 2020-06-30 | $713.00K 6-K · filed 2021-08-05 | ||||
| 2018-12-31 | $3.42M 20-F · filed 2019-04-01 | ||||
| 2017-12-31 | $2.23M 20-F · filed 2019-04-01 | ||||
| 2016-12-31 | $3.56M 20-F · filed 2019-04-01 | ||||
| 2015-12-31 | $4.75M 20-F · filed 2018-03-28 |